Previous 10 | Next 10 |
Aileron Therapeutics ( NASDAQ: ALRN ) shed ~38% on Tuesday after the company disclosed plans to explore strategic alternatives, including a sale, and said that its Phase 1b study for chemoprotective agent ALRN-6924 failed in patients with p53-mutated breast cancer. The open-label ...
BOSTON, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN) today announced that a review of initial data from its Phase 1b chemoprotection trial of ALRN-6924 in patients with p53-mutated breast cancer showed that patients in the trial experienced severe neutropenia (Grade 4) an...
BOSTON, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it received written notice on November 28, 2022 from The N...
BOSTON, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that it will effect a 1-for-20 reverse stock split of its...
Aileron Therapeutics press release ( NASDAQ: ALRN ): Q3 GAAP EPS of -$0.07 beats by $0.01 . Cash, cash equivalents, and investments on September 30, 2022, were $25.5 million, compared to $45.9 million on December 31, 2021. For further details see: Aileron The...
Activated multiple existing and new sites under amended Phase 1b breast cancer clinical trial protocol; additional site activations anticipated in 4Q 2022 and 1Q 2023 Presented healthy volunteer study results at EORTC-NCI-AACR International Conference demonstrating potential of ALRN-6...
p53-mediated cell cycle arrest results demonstrate potential of ALRN-6924 to prevent chemotherapy-induced neutropenia, thrombocytopenia, and anemia, as well as chemotherapy-induced alopecia (hair loss) Study showed greater degree and longer duration of effect for ALRN-6924 at higher d...
New ex vivo data demonstrates protection against cyclophosphamide-induced damage to hair follicles and their stem cells Encore presentation of data presented at Society for Investigative Dermatology in May 2022 shows: ALRN-6924 temporarily arrested the cell cycle in human scalp ...
BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that Manuel Aivado, M.D., Ph.D., President and Chief Exe...
BOSTON, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy safer and thereby more effective to save more patients’ lives, today announced that a pre-recorded corporate presentation by Manuel Aiv...
News, Short Squeeze, Breakout and More Instantly...
Aileron Therapeutics Inc. Company Name:
ALRN Stock Symbol:
NASDAQ Market:
Aileron Therapeutics Inc. Website:
Aileron Therapeutics to be Included in the Russell Microcap® Index PR Newswire AUSTIN, Texas , July 1, 2024 /PRNewswire/ -- Aileron Therapeutics, Inc. ("Aileron" or the "Company") (NASDAQ: ALRN), a biopharmaceutical company advancing a novel pipeline of...
Announced positive data from Cohort 1 of the Phase 1b clinical trial of LTI-03 in idiopathic pulmonary fibrosis (IPF) patients with positive trends observed in seven of the eight biomarkers evaluated Topline results from Cohort 2 evaluating high-dose LTI-03 (5 mg BID) expected in ...
Aileron Therapeutics Inc. (ALRN) is expected to report for Q1 2024 DZS Inc. (DZSI) is expected to report $-0.09 for Q1 2024 Bitfarms Ltd. (BITF) is expected to report $-0.03 for Q1 2024 180 Degree Capital Corp. (TURN) is expected to report for quarter end 2024-03-31 Abacus Life In...